Targeted therapies for renal cell carcinoma von Posadas, Edwin M., Limvorasak, Suwicha, Figlin, Robert A.

Volltext

Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis von Wu, Xiwei, Weng, Lihong, Li, Xuejun, Guo, Chao, Pal, Sumanta K, Jin, Jennifer M, Li, Yuping, Nelson, Rebecca A, Mu, Bing, Onami, Susan H, Wu, Jeffrey J, Ruel, Nora H, Wilczynski, Sharon P, Gao, Hanlin, Covarrubias, Maricela, Figlin, Robert A, Weiss, Lawrence M, Wu, Huiqing

Volltext

S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites von Deng, Jiehui, Liu, Yong, Lee, Heehyoung, Herrmann, Andreas, Zhang, Wang, Zhang, Chunyan, Shen, Shudan, Priceman, Saul J., Kujawski, Maciej, Pal, Sumanta K., Raubitschek, Andrew, Hoon, Dave S.B., Forman, Stephen, Figlin, Robert A., Liu, Jie, Jove, Richard, Yu, Hua

Volltext

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma von Motzer, Robert J., Escudier, Bernard, Gannon, Andrew, Figlin, Robert A.

Volltext

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma von Courtney, Kevin D, Infante, Jeffrey R, Lam, Elaine T, Figlin, Robert A, Rini, Brian I, Brugarolas, James, Zojwalla, Naseem J, Lowe, Ann M, Wang, Keshi, Wallace, Eli M, Josey, John A, Choueiri, Toni K

Volltext

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial von Motzer, Robert J, Dr, Prof, Escudier, Bernard, MD, Oudard, Stéphane, Prof, Hutson, Thomas E, Prof, Porta, Camillo, MD, Bracarda, Sergio, MD, Grünwald, Viktor, Prof, Thompson, John A, Prof, Figlin, Robert A, Prof, Hollaender, Norbert, PhD, Urbanowitz, Gladys, BS, Berg, William J, MD, Kay, Andrea, MD, Lebwohl, David, MD, Ravaud, Alain, Prof

Volltext

Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors von Figlin, Robert A., Kaufmann, Isabelle, Brechbiel, Jillian

Volltext

Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework von Lakdawalla, Darius N., PhD, Shafrin, Jason, PhD, Hou, Ningqi, PhD, Peneva, Desi, MS, Vine, Seanna, MPH, Park, Jinhee, PhD, Zhang, Jie, PhD, Brookmeyer, Ron, PhD, Figlin, Robert A., MD, FACP

Volltext

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma von MOTZER, Robert J, HUTSON, Thomas E, GARCIA-DEL-MURO, Xavier, SOSMAN, Jeffrey A, SOLSKA, Ewa, WILDING, George, THOMPSON, John A, KIM, Sindy T, CHEN, Isan, XIN HUANG, FIGLIN, Robert A, TOMCZAK, Piotr, MICHAELSON, M. Dror, BUKOWSKI, Ronald M, OUDARD, Stéphane, NEGRIER, Sylvie, SZCZYLIK, Cezary, PILI, Roberto, BJARNASON, Georg A

Volltext

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) von Rini, Brian I., Battle, Dena, Figlin, Robert A., George, Daniel J., Hammers, Hans, Hutson, Tom, Jonasch, Eric, Joseph, Richard W., McDermott, David F., Motzer, Robert J., Pal, Sumanta K., Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.

Volltext

A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models von Zhang, Hao, Berel, Dror, Wang, Yanping, Li, Ping, Bhowmick, Neil A, Figlin, Robert A, Kim, Hyung L

Volltext

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib von RINI, Brian I, COHEN, Darrel P, LU, Dongrui R, CHEN, Isan, HARIHARAN, Subramanian, GORE, Martin E, FIGLIN, Robert A, BAUM, Michael S, MOTZER, Robert J

Volltext

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma von Rosenberg, Jonathan E., Bambury, Richard M., Van Allen, Eliezer M., Drabkin, Harry A., Lara, Primo N., Harzstark, Andrea L., Wagle, Nikhil, Figlin, Robert A., Smith, Gregory W., Garraway, Levi A., Choueiri, Toni, Erlandsson, Fredrik, Laber, Damian A.

Volltext

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells von Xin, Hong, Zhang, Chunyan, Herrmann, Andreas, Du, Yan, Figlin, Robert, Yu, Hua

Volltext

Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors von MOTZER, Robert J, ESCUDIER, Bernard, KAY, Andrea, RAVAUD, Alain, OUDARD, Stephane, HUTSON, Thomas E, PORTA, Camillo, BRACARDA, Sergio, GRÜNWALD, Viktor, THOMPSON, John A, FIGLIN, Robert A, HOLLAENDER, Norbert

Volltext

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma von MOTZER, Robert J, HUTSON, Thomas E, BELLO, Akintunde, KORYTOWSKY, Beata, JINYU YUAN, VALOTA, Olga, MARTELL, Bridget, HARIHARAN, Subramanian, FIGLIN, Robert A, OLSEN, Mark R, HUDES, Gary R, BURKE, John M, EDENFIELD, William J, WILDING, George, AGARWAL, Neeraj, THOMPSON, John A, CELLA, David

Volltext

COVID-19 and androgen-targeted therapy for prostate cancer patients von Bhowmick, Neil A, Oft, Jillian, Dorff, Tanya, Pal, Sumanta, Agarwal, Neeraj, Figlin, Robert A, Posadas, Edwin M, Freedland, Stephen J, Gong, Jun

Volltext

Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer von Shaw, Tiffany Y., Lee, Hannah, Figlin, Robert A.

Volltext

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase... von Tran, Hai T, PharmD, Liu, Yuan, PhD, Zurita, Amado J, MD, Lin, Ying, PhD, Baker-Neblett, Katherine L, MBA, Martin, Anne-Marie, PhD, Figlin, Robert A, MD, Hutson, Thomas E, DO, Sternberg, Cora N, MD, Amado, Rafael G, MD, Pandite, Lini N, MD, Heymach, John V, Dr

Volltext

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma von Courtney, Kevin D., Ma, Yuanqing, de Leon, Alberto Diaz, Christie, Alana, Xie, Zhiqun, Woolford, Layton, Singla, Nirmish, Joyce, Allison, Hill, Haley, Madhuranthakam, Ananth J., Yuan, Qing, Xi, Yin, Zhang, Yue, Chang, Jenny, Fatunde, Oluwatomilade, Arriaga, Yull, Frankel, Arthur E., Kalva, Sanjeeva, Zhang, Song, McKenzie, Tiffani, Torras, Oscar Reig, Figlin, Robert A., Rini, Brian, McKay, Renee M., Kapur, Payal, Wang, Tao, Pedrosa, Ivan, Brugarolas, James

Volltext